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Type 1 diabetes (T1D) is a chronic autoimmune disorder characterized by destruction of insulin-producing
pancreatic b cells. Many broad-based immunosuppressive and antigen-specific immunoregulatory thera-
pies have been and are currently being evaluated for their utility in the prevention and treatment of T1D. Look-
ing forward, this review discusses the potential therapeutic use of antigen-specific tolerance strategies,
including tolerance induced by ‘‘tolerogenic’’ antigen-presenting cells pulsed with diabetogenic antigens
and transfer of induced or expanded regulatory T cells, which have demonstrated efficacy in nonobese
diabetic (NOD) mice. Depending on the time of therapeutic intervention in the T1D disease process,
antigen-specific immunoregulatory strategies may be employed as monotherapies, or in combination with
short-term tolerance-promoting immunoregulatory drugs and/or drugs promoting differentiation of insulin-
producing b cells from endogenous progenitors.Introduction
Type 1 diabetes (T1D) is a chronic autoimmune disorder thought
to be caused by proinflammatory autoreactive T cells, which
mediate the destruction of insulin-producing pancreatic b cells
via both direct and indirect mechanisms leading to life-long
dependence on exogenous insulin (Atkinson and Eisenbarth,
2001). Development of T1D is genetically controlled and thought
to be initiated in susceptible individuals by environmental factors
such as virus infections, although a viral cause has not been
clearly identified (von Herrath, 2009). Although both humoral
and cell-mediated immune mechanisms are active during dia-
betes, CD4+ T cells occupy a critical role in T1D pathology
(Anderson and Bluestone, 2005), as exemplified by the observa-
tion that the majority of the genes associated with elevated
disease risk relate to the function of CD4+ Th cells (e.g., a trio
of major histocompatibility complex class II [MHC II] alleles
[Concannon et al., 2009]). Prior to diagnosis of overt T1D, the
pancreatic islets are infiltrated by inflammatory cells including
CD4+ T cells (Kent et al., 2005), and antibodies to various b cell
antigens are demonstrable in the sera of patients at risk (Achen-
bach et al., 2005).
Because of the ocular, circulatory, cardiovascular, and neuro-
logical risks associated with hyperglycemia, treatments that
prevent the pathologic autoimmunity from destroying pancreatic
tissue is preferable to long-term management of symptoms by
insulin replacement therapy because use of exogenous insulin
cannot match the precision of endogenous insulin secretion.
Much of what is understood about the pathogenesis and regula-
tion of T1D has emerged from the study of spontaneous disease
in the nonobese diabetic (NOD) mouse. NOD studies have high-
lighted the critical role of adaptive immune responses in disease
pathogenesis as well as identifying various targets that prevent
diabetogenic autoimmune responses as prime therapeutic488 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.candidates (Atkinson and Leiter, 1999; Shoda et al., 2005).
However, it is critical to understand that there are numerous
differences in the pathogenic mechanisms driving the initiation
and progression of disease in the NOD mouse versus human
type 1 diabetics, e.g., major differences in the antigens targeted
and the composition of inflammatory cell infiltrates in the two
species, as well as greatly increased expression of MHC class
I in humans (Gianani et al., 2010).
Existing and emerging therapies aimed at regulating the
autoimmune response largely involve broad-based immunoreg-
ulatory strategies, including the inhibition or deletion of lympho-
cyte subsets and/or the use of agents proposed to induce or
re-establish immune tolerance via activation of regulatory T
(Treg) cells, e.g., nonmitogenic anti-CD3 or antithymocyte glob-
ulin (Chatenoud, 2003; Chatenoud et al., 2001; Chung et al.,
2007; Kohm et al., 2005). Some of these have shown efficacy
in initial clinical trials, but there are risks with any of the broad
approaches such as cytokine release and/or reactivation of
latent viruses. A highly desired alternative approach is the
attempted induction of antigen-specific tolerance to b cell anti-
gens for prevention of disease development in patients at risk
or in new-onset patients. This review will discuss immunoregula-
tory strategies employed as monotherapies or in combination,
including the use of antigen-specific tolerance strategies, which
are under evaluation in clinical trials and/or are being developed
based on demonstrated efficacy in preventing or ameliorating
disease progression in the NOD mice.
There are numerous pitfalls to the translation of laboratory
findings to the clinic. Trials of therapies that alter the natural
history of T1D have been hampered by the lack of biomarkers
of the immune processes that cause the disease. There are
immunologic ‘‘readouts’’ that correlate with the presence of
T1D; for instance, the presence of autoantibodies against islet
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insulin, islet cell antigen 512 (ICA512), and more recently zinc
transporter 8 (ZnT8) has supported the autoimmune nature of
the disease and has clearly differentiated T1D from type 2 dia-
betes where these markers are not found (Seyfert-Margolis
et al., 2006). More recently, cellular proliferation assays to islet-
specific proteins have distinguished responses in patients
from normal control subjects (Herold et al., 2009). Other assays
have identified antigen-specific cells in the circulation (Pinkse
et al., 2005). However, the direct causal relationship between
these measures and disease has not yet been established. For
instance, in studies in which glycemic control has been modified
(e.g., Cyclosporin A [CSA] or anti-CD3 monoclonal antibody
[mAb]), there were no identified changes in titers of autoanti-
bodies (Bougne`res et al., 1988; Herold et al., 2002, 2005; Key-
meulen et al., 2005). Thus, an assay that would reflect tolerance
to the immune process in T1D is not currently available but is
highly sought after.
Immunologic assays may be used as measures of the effects
of immune therapies, but their relationship to the disease
process remains speculative. One is left with metabolic parame-
ters as endpoints. Although the relationship of these endpoints
to the clinical situation is clearer, it is important to recognize
that the most widely employed studies are functional, not
anatomic. For example, in murine studies of treatment with
CD3 mAb at the diagnosis of T1D in NOD mice, improvement
in insulin secretion reflected the recovery of degranulated b cells
rather than growth of new cells (Sherry et al., 2006). Even the
relationship between improved metabolic function and the
sequelae of the disease is controversial, but clinical data have
suggested a direct relationship between the two (Palmer et al.,
2004).
Chemical- and Antibody-Mediated Therapies
Initial clinical studies for treatment of T1D involved small-mole-
cule inhibitors with biologics undergoing evaluation in the past
decades. These clinical trials have had successes and failures
as summarized in Table 1. The following narrative explains the
basis for and findings of these trials.
Cyclosporin A
CSA was employed in the first trials showing effects of immune
therapies on T1D. Continuous CSA treatment initiated soon after
diagnosis eliminated the need for exogenous insulin (Bougne`res
et al., 1988; Stiller et al., 1984). However, the lack of lasting
effects and renal toxicity of the drug diminished enthusiasm for
this approach and other broad-spectrum immune-modulating
agents such as Azathioprine and Prednisone (Bougne`res et al.,
1990; Silverstein et al., 1988).
CD3 Monoclonal Antibody
CD3 mAb without Fc receptor (FcR) binding was developed with
the goal of reducing T cell activation butmaintaining immunoreg-
ulatory capacity in vivo via suboptimal TCR signals and/or induc-
tion of Treg cells. Preclinical studies indicated, however, that not
only was in vivo activation quantitatively reduced, but the signal
delivered by the modified Ab was also qualitatively different from
FcR binding mAb (Belghith et al., 2003; Smith et al., 1997, 1998).
These studies indicated a selective inhibitory effect on differen-
tiated Th1 cells, which had been thought to be involved in
b cell destruction. Rather than a direct inhibitory effect of thedrug, which would require the continued presence of the agent,
tolerance was achieved probably via induction of Treg cells.
Disease did not recur over time after short-term treatment of
newly hyperglycemic mice, and if treated mice did not
completely reverse hyperglycemia after drug treatment, they
did not destroy syngeneic transplants after anti-CD3 mAb treat-
ment (Chatenoud et al., 1994, 1997).
FcR nonbinding anti-CD3 mAbs carrying mutations of the
IgG1 Fc chain or with elimination of glycosylation sites [hOKT3-
g1(Ala-Ala) and aglycosyl anti-CD3] were found to be less acti-
vating than OKT3 (Bisikirska et al., 2005; Herold et al., 2003;
Xu et al., 2000). In two trials, brief treatment of new-onset
T1D patients was shown to attenuate loss of b cell function
for R 2 years (Herold et al., 2002, 2005; Keymeulen et al.,
2005). Clinical parameters including hemoglobin A1c and insulin
usage improved. Importantly, there was no evidence for long-
term immune suppression. Circulating T cell numbers recovered
to pretreatment levels by onemonth after treatment and the drug
was well tolerated—the cytokine storm had largely been elimi-
nated, although about 10% of subjects discontinued drug
because of adverse events attributed to cytokine release. In
the European trial, in which the number of circulating T cells
was less than that in the North American trial, Epstein-Barr virus
(EBV) reactivation was seen, but in all cases the infection
resolved, and the reduced numbers of circulating lymphocytes
were transient.
Children who are relatives of patients with T1D and have islet
cell autoantibodies are at extraordinarily high risk for progression
to diabetes. About 90% of subjects who meet these criteria,
identified in the Diabetes Prevention Trial-1 (DPT-1), will have
clinical disease within 7 years, and the median time to disease
onset is 3.31 years (Sherr et al., 2008). The progression of
b cell destruction in these individuals, therefore, resembles those
with disease, and therefore because of the near certainty that
disease will progress, interventions that have shown efficacy in
subjects with diabetes could be considered in this group.
Accordingly, TrialNet has initiated a trial of anti-CD3 mAb treat-
ment in individuals at high risk of diabetes. Based on information
from clinical trials in patients with the disease, the suggested
outcome is maintenance of insulin secretion and prevention of
disease onset.
The mechanism of drug action in patents is not resolved but
may differ from that described in NOD mice. In this regard,
Herold et al. (2003) isolated IL-10-producing CD4+ cells from the
circulation of drug-treated patients, and there was an increase
in the relative ratio of production of IL-10:IFN-g in patient cells
activated ex vivo. An increase in adaptive CD4+CD25+Foxp3+
cells that inhibit immune responses through a TGF-b-dependent
mechanism has been found in the pancreatic draining lymph
nodes of anti-CD3-treated mice, even in the absence of naturally
occurring Treg cells (i.e., in CD28/mice) (Belghith et al., 2003;
Bisikirska et al., 2005). It is not clear whether the same cells
can be found in the circulation of patients. It has also been sug-
gested that the mAb induces adaptive CD8+ Treg cells whose
mechanism of inhibition is not clear and may be similar to
CD8+ suppressor cells described in other clinical settings. The
absence of a tolerance biomarker or even a functional assay
that correlates with the pathogenic process has made it difficult
to answer whether the drug induces tolerance in patients.Immunity 32, April 23, 2010 ª2010 Elsevier Inc. 489
Table 1. Summary of Successful and Unsuccessful Immunotherapy-Based Approaches in Type 1 Diabetes and Relevant Animal
Models
Therapy Efficacy in Animal Model Comments Principle Adverse Events References
Successful Clinical Trials
Cyclosporine A + NOD mouse,
BB/W rat
Continued use of the
drug was needed
Renal toxicity (Assan et al., 1994; Bougne`res
et al., 1988, 1990; Feutren et al.,
1986; Laupacis et al., 1983;
Mori et al., 1986; Stiller
et al., 1984)
Antithymocyte
globulin (alone or
with Prednisone)
+ NOD mouse with
Exendin-4, not as
single agent
Also part of a hematopoietic
stem cell transplant protocol
Thrombocytopenia,
serum sickness
(Eisenbarth et al., 1985;
Ogawa et al., 2004; Saudek
et al., 2004; Simon et al., 2008;
Voltarelli et al., 2007)
Anti-CD3 mAb + NOD mouse Late timing was an issue
in the first report but not
in the second report
Mild transient cytokine
release, transient EBV
reactivation
(Chatenoud et al., 1994, 1997;
Herold et al., 1992, 2002, 2005;
Keymeulen et al., 2005)
Rituximab + NOD mouse Grade 1 or 2
infusion-related reactions
(Hu et al., 2007; Pescovitz
et al., 2009)
Etanercept + NOD mouse but
depending on timing:
 for older mice
Pilot human trial No significant drug-related
adverse events
(Jacob et al., 1990;
Mastrandrea et al., 2009)
GAD65 + NOD mouse Only in those with
diabetes < 6 months
duration
Mild site irritation, no
significant drug-related
adverse events
(Agardh et al., 2005;
Ludvigsson et al., 2008;
Tian et al., 1996; Tisch
et al., 1993)
Oral insulin
(Prevention)
+ NOD mouse Only a subset of prediabetic
subjects with high IAA titer
No significant drug-related
adverse events
(Skyler et al., 2005;
Zhang et al., 1991)
Closed-loop
insulin
A ‘‘biostator’’ (closed-loop
system) was used and
suppressed endogenous
insulin production. No
immune therapy was given
Hypoglycemia (Shah et al., 1989)
Unsuccessful Clinical Trials
Nicotinamide + NOD mouse No significant drug-related
adverse events
(Gale et al., 2004; Kolb and
Burkart, 1999; O’Brien
et al., 2000; Yamada
et al., 1982)
Intranasal insulin + NOD mouse Nasal irritation and
discharge, cough, fever,
GI symptoms
(Bonifacio et al., 2008; Every
et al., 2006; Harrison et al., 2004;
Na¨nto¨-Salonen et al., 2008)
Parenteral insulin + NOD mouse A pilot clinical trial
showed efficacy
Chemical hypoglycemia (Atkinson et al., 1990; Diabetes
Prevention Trial–Type 1 Diabetes
Study Group, 2002)
Oral insulin + NOD mouse See above. A change
in the IAA titer for inclusion
appeared to result in
dilution of the drug effect
No significant drug-related
adverse events
(Skyler et al., 2005;
Zhang et al., 1991)
Insulin in incomplete
Freund’s adjuvant
+ NOD mouse Small pilot trial, generated
high titers of insulin
antibodies
No significant drug-related
adverse events
(Orban et al., 2009;
Skyler et al., 2005;
Zhang et al., 1991)
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Antithymocyte Globulin (ATG) with prednisone had been shown
to reduce insulin requirements in a pilot trial involving new-onset
patients but was discontinued because of thrombocytopenia
(Eisenbarth et al., 1985). In a more recent study, ATG (Fresinius)
retarded the loss of C peptide (which correlates with loss of
pancreatic b cell function) in new-onset patients without the
need for continuous drug administration (Saudek et al., 2004).490 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.The importance of the multiple specificities of ATG compared
to anti-CD3 or other anti-T cell mAbs is not known—CD3 is an
important target of ATG, but ATG causes a more prolonged
peripheral T cell depletion. Thus the effects of these two bio-
logics on the T cell repertoire may be different.
Anti-CD20
Anti-CD20 (Rituximab) was recently employed in a T1D trial. B
lymphocytes were first thought to be important in the initiation
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in B cell-deficient NOD mice (Serreze et al., 1996). Previous
evidence, however, had questioned B cell-directed therapeutic
approaches in established disease because it was possible to
adoptively transfer disease with diabetogenic splenic T cells
into NOD.SCID recipients, lacking B cells and antibodies (Miller
et al., 1988). Hu et al. (2007) and Xiu et al. (2008) recently showed
that diabetes was prevented in NOD mice by depleting B cells
with CD20 mAb before and at the time of onset of hyperglycemia
(9–12-week-old mice) and even reversed disease in about 30%
of animals at the appearance of hyperglycemia. Interestingly,
cotransfer of B cells from the successfully treated mice dimin-
ished the rate of adoptive transfer of disease, suggesting a
possible role for activation of ‘‘regulatory’’ B cells. Others have
since shown that IL-10-producing B cells can be induced in
mice depleted of CD20+ B cells (Yanaba et al., 2008).
A recent randomized placebo-controlled trial of CD20 mAb
(Rituximab) showed modest (23%) but significant improvement
in b cell function 3 months after diagnosis and overall at 1 year,
in drug-treated compared to placebo-treated subjects (Pesco-
vitz et al., 2009). There were also significant improvements in
clinical parameters including hemoglobin A1c and insulin use.
After 3 months, however, there was a parallel decline in b cell
function in the drug- and placebo-treated subjects. Subtle but
significant differences in the depletion of CD19+CD27+IgD+ cells
differentiated clinical responders fromnonresponders. However,
there was little evidence that the drug induced immunologic
tolerance. The CD19+ cells, which reached a nadir level at study
month 1, had not recovered to control levels after 12months, and
the levels of IgM were still significantly depressed. Once again,
maintenance of clinical efficacy will require either a combination
of drugs or repeated treatment, but the chronicity of immune
suppression is of concern.
Cytokine- and Cytokine-Receptor-Directed Therapies
Cytokine- and cytokine-receptor-directed therapies are also in
development for treatment of T1D. Human insulitis shows
a considerably greater infiltration of innate immune cells such
as macrophages and natural killer (NK) T cells compared to
NOD insulitis (Dotta et al., 2007; Itoh et al., 1993). Moreover,
innate mediators (TNF-a, IL-1, and type 1 interferons) were
among the first molecules shown to have direct cytotoxic effects
on b cells and were postulated to be the direct cause of b cell
killing (Rabinovitch et al., 1990). Possibly because of its innate
role in activating adaptive immune responses, it was not
surprising that IL-1 receptor-deficient NOD mice had reduced
development of diabetes (Thomas et al., 2004). Treatment with
the IL-1 receptor antagonist, Anakinra, was shown to improve
glucose control in patients with type 2 diabetes, which is not
thought to be mediated by adaptive immune responses but has
a significant inflammatory component (Donath and Mandrup-
Poulsen, 2008). Interestingly, the drug mechanism appeared to
involve a beneficial effect on b cells, reflected by an increase in
the insulin:proinsulin ratio, rather than effect on reduced insulin
sensitivity that had been thought to be the result of the inflamma-
tory cytokine. b cells may be a source of IL-1, particularly in
response to glucose, suggesting a destructive cycle in which
hyperglycemia induces expression of the inflammatory mediator
resulting in immune activation and further b cell destruction.
Initial preclinical data do not suggest that IL-1 blockade alonewill prevent or reverse type 1 diabetes, but this axis may be an
important target of a combination strategy. Studies to evaluate
the effects of IL-1 blockade in disease progression are in
progress.
TNF-a and IFN-g are directly cytotoxic to b cells, suggesting
these cytokines as rational targets for immune therapy. How-
ever, TNF-a has a more complicated role in diabetes progres-
sion. Jacob et al. (1990) reported that TNF-a prevented develop-
ment of insulitis and diabetes and even the adoptive transfer of
diabetes by lymphocytes into young NOD mice. Moreover,
neutralization of TNF-a accelerated diabetes in older mice but
prevented disease at a younger age. These paradoxical effects
may have led to reluctance for clinical translation, but a recent
report by Mastrandrea et al. (2009) found that the soluble TNF
receptor, Etanercept, reduced loss of C peptide responses in
a small pilot trial.
Small-Molecule Protease Inhibitor Therapy
Small-molecule protease inhibitors are also under development
for the treatment of T1D. The role of innate immune responses in
T1D pathogenesis is further supported by the study by Koul-
manda et al. (2008) in which infusions of alpha-1 antitrypsin
(AAT), a serine protease inhibitor that protects tissues from
enzymes produced from inflammatory cells, were found to
reverse new-onset diabetes in NOD mice. Multiple effects were
noted in the NOD studies including reduced insulitis, enhanced
b cell regeneration, and improvement in peripheral insulin sensi-
tivity. This nonconventional approach is now in clinical testing.
The small-molecule tyrosine kinase inhibitor, Gleevec, used
widely for treatment of leukemia, was shown to prevent and
reverse diabetes in NOD mice (Louvet et al., 2008). The effects
appeared to be linked to inhibition of platelet-derived growth
factor receptor (PDGFR) because targeting c-Abl kinase with
sunitinib or c-Kit kinase and c-Fms kinase with another tyrosine
kinase inhibitor showed marginal efficacy whereas soluble
PDGFR reversed diabetes.
Aggressive Insulin Therapy
Lastly, aggressive insulin therapy has been tested for therapeutic
efficacy in T1D. Shah et al. (1989) showed that use of a closed-
loop system, in which patients with new-onset T1D were admin-
istered insulin to suppress endogenous insulin production,
resulted in improved metabolic function, similar to more recent
trials of immune modulators. It was possible that the intensive
insulin therapy had an immune-modulatory effect, but this early
observation also raises the question of whether reducing meta-
bolic demand on the targets themselves might alter the immune
response to islets.
Antigen-Specific Tolerance Approaches to T1D Therapy
The gold standard therapy for the treatment of autoimmune
diseases, including T1D, would be the development treatment
strategies in which only the pathogenic autoreactive T cells are
inactivated safely and in an autoantigen-specific manner while
leaving the remainder of immune system unperturbed, i.e., the
induction antigen-specific immunologic tolerance. There are
multiple strategies under development and/or currently being
evaluated in T1D trials that are proposed to targetmultiple diabe-
togenic antigens and have been demonstrated to operative via
a number of cell-intrinsic (anergy) and/or cell-extrinsic (Treg
cells) mechanisms.Immunity 32, April 23, 2010 ª2010 Elsevier Inc. 491
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Insulin therapy has been widely studied in both animal models of
T1D as well as in human prevention and new-onset trials. In
several autoimmune diseasemodels, mucosal exposure to auto-
antigens induces tolerance largely via induction of a variety of
Treg cells (Faria and Weiner, 2005). Insulin and proinsulin mole-
cules have been identified to play a prime role in the initiation of
the autoimmune process that ultimately leads to destruction of
b cells and onset of clinical diabetes. Since the early 1990s,
mucosal exposure of insulin and many of its immunogenic
epitopes has been used for diabetes prevention in animal
models. Oral insulin at a dose of 1 mg twice a week for 5 weeks
followed by weekly treatment was able to delay diabetes onset
and reduce diabetes incidence in NOD mice (Zhang et al.,
1991). Adjuvants such as cholera toxin B subunit could signifi-
cantly reduce the amount of antigen (insulin) needed to micro-
gram amounts (Bergerot et al., 1997). Similarly to oral treatment,
intranasal aerosol insulin treatment of prediabetic NODmice also
significantly delayed diabetes incidence in NOD mice (Aspord
and Thivolet, 2002; Harrison et al., 1996). In addition to whole
insulin, insulin-derived peptides, such as B9-23, mutated proin-
sulin peptide B24-C33, and proinsulin II, have also been shown
to be efficacious in prediabetic NOD mice (Chen et al., 2001;
Daniel and Wegmann, 1996; Martinez et al., 2003).
Despite the persistence of even ‘‘clinically significant’’ levels of
residual insulin and the potential for recovery of dysfunctional
b cells with immune therapy at the time of diagnosis, prevention
of T1D will have a greater impact than treatment approaches.
Autoimmunity to islets can be identified R three years before
presentation with hyperglycemia in many individuals. Interven-
tions that are effective at onset would be postulated to be effec-
tive in the prediabetic period. In addition, by intervening at an
early stage, antigen-specific approaches might be more effec-
tive because the repertoire is more restricted and the number
of different effectors that are involved is more restricted. Based
on the success in animal models, clinical trials of oral or nasal
insulin have been conducted in humans. These trials can be
divided into prevention trials in prediabetics and therapeutic
trials in recent-onset diabetics.
Human prevention trials have included a double-blinded
crossover safety study conducted in 38 individuals with anti-
bodies to one or more islet antigens which showed that intra-
nasal insulin was safe in that it did not accelerate loss of b cell
function in individuals at risk for type 1 diabetes but instead
induced an increase in antibody and a decrease in T cell
responses to insulin consistent with mucosal tolerance (Harrison
et al., 2004). The subsequent DPT-1 tested the efficacy of oral
insulin in 388 prediabetic patients who were first- and second-
degree relatives of T1D patients and were also classified as at
increased risk for developing T1D by genetic, immunological,
and metabolic staging (Skyler et al., 2005; Sosenko et al.,
2006). Oral insulin therapy did not delay or prevent type 1 dia-
betes. However, in subgroup analysis, it appeared that there
might be a potential benefit in diabetes prevention in those
subjects with higher autoantibody levels. A more recent preven-
tion trial using intranasal insulin conducted in 224Finnish children
with genetic and immunological risks for developing T1D showed
that nasal insulin administration at 1 unit/kg/day initiated soon
after detection of autoantibodies had no beneficial effect on dia-492 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.betes prevention (Na¨nto¨-Salonen et al., 2008). Furthermore, chil-
dren positive for three of four autoantibodies before initiation of
treatment appeared to be at possibly increased risk for acceler-
ated onset of diabetes. This is a classic example ofwhere preclin-
ical studies were not predictive of the outcome of a human trial.
Several explanations have been offered for the failure of
these trials, including insufficient dosing as well as the fact that
by the time an individual is identified with autoantibodies, the
disease process is well established. Therefore, the opportunity
to intervene before the autoreactive repertoire is expanded via
epitope spreading (Miller et al., 2007), i.e., before the appear-
ance of multiple autoantibodies, using tolerance strategies with
or without broader immunosuppressive agents, should be
further explored. In addition, this may also reflect the complexity
of mucosal immunology. Depending on pre-existing milieu,
both tolerance and immunity are potential outcomes after
mucosal antigen exposures. This could explain why possible
disease acceleration has been observed with mucosal insulin
therapy in certain subpopulations. Again, understanding indi-
vidual immune responses elicited by mucosal insulin therapy
based on the dose, route, frequency, duration, and stage of
disease at which therapy is instituted will probably significantly
enhance our ability to design individualized mucosal insulin
therapy that will be safe and efficacious.
There have been a number of human new-onset trials using
insulin therapy. Two published trials examined the effect of oral
insulin therapy on residual b cell function in recent-onset T1D
patients. In the immunotherapy diabetes (IMDIAB) trial, a total
of 82 patients with clinical type 1 diabetes were randomized to
receive oral insulin at 5 mg/day or placebo (Pozzilli et al.,
2000). At a 1 year follow-up, there was no difference between
the insulin-treated and the placebo-treated groups with respect
to mean C-peptide secretion, requirement for insulin therapy,
or IgG insulin antibodies. Furthermore, in patients younger than
15 years, a tendency for low C-peptide at 9 and 12 months
was observed in the oral insulin group, suggesting an accelera-
tion in the decline of b cell function. In the Diabete Insuline Orale
group (ORALE) trial, 131 new-onset T1D patients were random-
ized to a low-dose (2.5 mg/day) or a high-dose (7.5 mg/day) oral
insulin versus placebo for 1 year, and again no benefit was
observed in preventing deterioration of b cell function (Chaillous
et al., 2000). These results are consistent with those seen in
murine models where oral insulin was shown not to reverse
new-onset diabetes (Fousteri et al., 2007). Interestingly, if nasal
insulin therapy is used in combination with anti-CD3 therapy,
a significant benefit in reversing recent-onset diabetes is
then achieved in two animal models of autoimmune diabetes
(Bresson et al., 2006). Expansion of insulin-specific Treg cells
producing IL-10, TGF-b, and IL-4, and possibly their modulation
of antigen-presenting cells in local draining lymph nodes, were
proposed as likely mechanisms. These findings should provide
the basis for using combinatorial therapies in future trials for
humans with recent-onset diabetes as discussed below.
Interestingly, a more recent phase I study using a single intra-
muscular injection of human insulin B chain in incomplete
Freund’s adjuvant in 12 subjects with recent-onset diabetes
showed that this therapy led to the development of lasting (at a
2 year follow-up) insulin B chain-specific CD4+ Treg cells (Orban
et al., 2009). This study provides the basis for testing this
Immunity
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ongoing phase I–II clinical trial of subcutaneous BHT-3021,
a plasmid encoding proinsulin, is testing the safety, dose, and
preliminary efficacy of this therapeutic modality in recent-onset
T1D patients (http://www.bayhilltherapeutics.com and http://
jdrf.org).
Glutamate Decarboxylase 65
Immune therapies targeting glutamate decarboxylase 65
(GAD65), an early target of autoantibodies during the initiation
of T1D (Kaufman et al., 1993; Tisch et al., 1993), have also
been tested in both animalmodels and human T1D. Interestingly,
the initial antigenic region is confined to a few epitopes near the
C terminus of the GAD protein but later spreads intramolecularly
to other GAD determinants, followed by further intermolecular
spreading to other b cell antigens. Consequently, tolerance
with intravenous or intrathymic injections of GAD in female
NOD mice at 3 weeks of age eliminates the anti-GAD T cell
responses, as well as subsequent spreading of the cascade of
T cell responses to other b cell antigens and the development
of insulitis or clinical diabetes (Tisch et al., 1993). Intravenous
injections of GAD during the later stages of disease still effec-
tively blocked disease progression in prediabetic mice and pro-
tected syngeneic islet graft survival in diabetic NOD mice (Tian
et al., 1996). The identification of CD4+ Treg cells in GAD-treated
mice suggests a major role for bystander suppression in the
induction of tolerance by treatment with this autoantigen, which
raises the question of whether GAD is targeted early in T1D
(Tisch et al., 1998).
Detection of GAD65 antibodies in the sera of prediabetic indi-
viduals is a reliable predictive marker for the progression to overt
diabetes (Leslie et al., 1999). Promising preclinical data in the
NOD model prompted two clinical trials using alum-formulated
human recombinant GAD65. A phase II safety and dose-finding
trial conducted in patients with latent autoimmune diabetes
in adults (LADA) (Agardh et al., 2005) showed the drug to be
safe, and administration of two 20 mg subcutaneous doses
1 month apart led to an increase of fasting and stimulated
C-peptide at 24 weeks compared to baseline, a benefit that was
associatedwithan increase inCD4+CD25+Tregcells. Thesecond
trial used the 20 mg dosing regimen in recent-onset T1D children
between10and18yearsof age (Ludvigssonet al., 2008). A slower
decline of fasting and stimulated C-peptide was observed in the
GAD-alum group compared to the placebo. More importantly,
the protective effect of GAD-alum was preferentially exhibited in
those who received treatment within 6 months of diagnosis,
suggesting that the autoimmune process is more susceptible to
GAD-based modulatory therapy if initiated at an earlier stage.
Heat Shock Protein
Therapies targeting heat shock protein (hsp) have also been
tested in animal models and human trials. Early controversies
existed as to whether heat shock proteins (hsp) were true auto-
antigens implicated in the pathogenesis of T1D (Atkinson et al.,
1991). However, extensive preclinical studies using the hsp60
peptide p277 demonstrated efficacy of peptide vaccination in
halting disease progression in the NOD mice (Elias and Cohen,
1995; Elias et al., 1991). p277 treatment appeared to promote
Th2 cell type response with upregulation of IL-10 and IL-13
and downregulation of IFN-g (Elias et al., 1997; Jin et al.,
2008). p277 also exerts inhibitory effects on the innate immunesystem via signaling through TLR-2, leading to inhibition of
inflammatory lymphocyte chemotaxis (Nussbaum et al., 2006).
The equivalent of human hsp60 p277 is a 24 amino acid
synthetic peptide derived from the C terminus of the human
hsp60, termed DiaPep277. Several phase I and II clinical trials
in human T1D patients have been completed in Europe, and
phase III trials are underway. A phase II trial was conducted in
patients with established T1D but with residual b cell function
(Huurman et al., 2007) and used a dose range of subcutaneously
administered DiaPep277. Results showed a trend of dose-
dependent preservation of stimulated C-peptide secretion.
Three additional trials were performed in new-onset T1D patients
(Lazar et al., 2007; Raz et al., 2001; Schloot et al., 2007). Two
of these trials enrolled adult TID patients, whereas the third
enrolled pediatric T1D patients. The adult trials showed signifi-
cantly better preservation of insulin synthesis as measured by
C-peptide production in the treated groups compared with
placebo, but this effect was not seen in the pediatric trial. Similar
results were observed in one other trial performed in pediatric
patients (Schloot et al., 2007), although in children with less
aggressive disease progression based on genetic background,
there appeared to be a trend to better preserved C-peptide at
the end of the study period. In summary, phase II trials with Dia-
Pep277 have shown some promise in preserving residual b cell
function, which appears to be less effective in patients with
more aggressive disease. A phase III trial is underway with
results expected in 2011.
Insulin-Coupled, ECDI-Fixed Antigen-Presenting Cells
An alternative technique for effective tolerance induction for
treatment of autoimmune diseases is the administration of
autoantigenic peptides covalently crosslinked to cellular vehi-
cles via ethylene carbodiimide (ECDI; reviewed in Miller et al.,
[2007]). In preclinical models of various autoimmune diseases,
this approach involves chemically crosslinking autoantigenic
proteins or peptides to syngeneic splenic leukocytes via ECDI
(Miller et al., 1979). It has been demonstrated that intravenous
injection of these antigen-coupled splenocytes (Ag-SPs) is
a highly efficacious method for the induction of tolerance for
both the prevention and the treatment of a variety of immune-
mediated disorders in animal models, including the experimental
autoimmune encephalomyelitis (EAE) model of multiple sclerosis
(MS) (Kennedy et al., 1990; Miller et al., 2007; Tan et al., 1992),
T1D in the NOD mouse (Fife et al., 2006) (S. Prahad, A.P.
Kohm, and S.D.M., unpublished data), and islet transplant rejec-
tion (Luo et al., 2008). Ag-SP tolerance induced by this method is
indirect in that the input Ag-SPs, which are induced to undergo
rapid apoptotic cell death after ECDI fixation (Turley and Miller,
2007), are uptaken in the host spleen, which is critical for toler-
ance induction because splenectomy abrogates tolerance
induction to both autoantigens and alloantigens (D.R. Getts,
A.M. Martin, X.L., and S.D.M., unpublished data). ECDI-fixed
cells accumulate in the splenic marginal zone and induce splenic
antigen presenting cells (APCs) to upregulate inhibitory costimu-
latory molecules (i.e., PD-L1) and to secrete regulatory cytokines
(i.e., IL-10 and TGF-b), leading to unresponsiveness via two
independent but synergistic mechanisms—T cell-intrinsic PD-
L1-PD-1-mediated anergy and activation of iTreg cells as
demonstrated for regulation of EAE (Miller et al., 2007), T1D
(Fife et al., 2006, 2009), and allogeneic islet cell transplantationImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 493
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Figure 1. Model of Epitope Spreading and
Tolerance Therapy in the Pathogenesis of
Type 1 Diabetes in the NOD Mouse
Progression of T1D in the NOD mouse involves
the sequential activation of autoreactive T cells to
multiple diabetogenic epitopes via epitope
spreading; these T cells accumulate until clinical
diagnosis when sufficient autoreactive effector
cells are present to cause destruction of the
majority of the b cell mass. The insulin B chain
epitope 9-23 (InsB9-23) (A, red effector cells)
appears to be the initiating or very early patho-
genic diabetogenic epitope in the NOD mouse on
the basis of the ability of tolerance induced by
ECDI-fixed splenocytes coupled with either intact
insulin or InsB9-23 in 4- to 6-week-old mice to
inhibit development of clinical diabetes (1). As
b cell destruction continues, responses to addi-
tional islet antigens, e.g., InsB15-23 and/or IRGP
(B, blue effector cells) and eventually epitopes on
the insulin A or B chains (C, green effector cells)
are activated. Epitopes on the InsA or InsB chain
(outside of B9-23) epitopes appear to be dominant
at the stage of transition to overt disease (loss of
approximately 75% of islet mass) based on the
ability of tolerance induced by insulin-coupled, but not InsB9-23-coupled, splenocytes to ameliorate disease progression in 18–20-week-old NOD mice (2).
Recovery from (i.e., reversal) chronic T1Dwhen all of the b cells have been destroyed would be expected to require a combination of tolerance to the autoantigens
that were responsible for initial b cell destruction and a b cell regeneration and/or replacement strategy thatmay require allo- or xenoantigen tolerance in therapies
involving islet cell transplantation (3). A similar pattern of epitope spreading is postulated to occur in human T1D.
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coupled to apoptotic Ag-SP debris by host splenic dendritic cells
gives this strategy the advantage that tolerance to autoantigenic
epitopes can be induced by cellular carriers fixed with intact
proteins or even crude homogenates of the disease target organ
(Kennedy et al., 1990). Themechanisms of Ag-APC tolerance are
fundamentally different from tolerance strategies using mucosal
antigen administration or alum injections in that unresponsive-
ness is exquisitely antigen specific and does not appear to
involve bystander suppression (Vanderlugt et al., 2000). This
tolerance induction method is currently being tested in a recently
initiated magnetic resonance imaging (MRI)-controlled phase I–
IIa clinical trial in new-onset relapsing-remitting MS patients at
the Center for Multiple Sclerosis, University of Hamburg,
Germany. The trial is examining the effects of tolerance induction
by using peptide-coupled, ECDI-fixed autologous peripheral
blood leukocytes (Ag-PBLs) coupled with a cocktail of seven
myelin peptides (encompassing immunodominant MS-associ-
ated CD4 T cell epitopes on three separate myelin proteins) in
an attempt to inhibit the potential of epitope spreading to
multiple endogenous myelin epitopes. A second clinical trial
using insulin-coupled PBLs for prevention of T1D is currently
under development by the Immune Tolerance Network (http://
www.immunetolerance.org). The ability to simultaneously target
multiple myelin epitopes has been demonstrated in several
mouse EAE models employing Ag-SP tolerance (Smith and
Miller, 2006) and is likely to be important in T1D because epitope
spreading is an important component of disease pathogenesis in
the NODmice (Figure 1). Disease appears to be initiated by T cell
responses to the immunodominant InsB9-23 epitope and then
spread to other insulin epitopes as illustrated by the finding
that tolerance induced in young NODs by splenocytes coupled
with either intact insulin or InsB9-23 inhibits development of
T1D, but prevention of new-onset disease (18–20 weeks in our
colony) can only be induced by tolerance to intact insulin (S. Pra-494 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.sad, A.P. Kohm, and S.D.M., unpublished data). This suggests
that InsB9-23 is an initiating diabetogenic epitope in NOD mice,
as supported by a recently reported genetic approach (Na-
kayama et al., 2005), and that the response evolves to target
other insulin epitopes outside of this region as mice transition
to overt hyperglycemia. A similar scenario of epitope spreading
is postulated to occur in human T1D and will influence the anti-
genic specificities needed to be targeted in tolerance-based
immunoregulatory strategies.
Combination Therapies
The lack of permanent remission of T1D with any single agent
suggests that combination therapiesmay be required for treating
T1D. A combination of approaches may be needed for effective
prevention of disease or reversal of new-onset T1D. Various
broader-spectrum immunoregulatory or suppressive agents
used in combination or together with antigen-specific tolerance
strategies have been tested in animal models of T1D and in
a limited number of clinical trials.
Because effector T cell responses are highly influenced by the
cytokines in the environment, combination of an agent that can
create a tolerogenic environment with a diabetogenic antigen
would be predicted to better modulate antigen response.
Synergy has been observed in reversal of diabetes in the NOD
and lymphocytic chroriomeningitis virus (LCMV) models of the
disease when insulin peptide was administered intranasally
together with anti-CD3 mAb (Bresson et al., 2006). Insulin
peptide-specific T cells isolated from these mice exhibited regu-
latory function and produced IL-10 and TGF-b in response
to antigen. This synergy probably involved both the reduction
of the ongoing response by the anti-CD3 mAb in combination
with the induction of antigen-specific Treg cells because
neither treatment alone was able to induce the antigen-specific
regulatory cells. Other drug combinations have shown syner-
gistic effects in the NOD T1D model, e.g., synergy between
IL-1 blockade with anti-CD3 mAb therapy (K.C.H., unpublished
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effector cells while promoting expansion of Treg cells, rapamycin
negated the effects of anti-CD3 mAb on diabetes in NOD mice
without altering the frequency or phenotype of T cells. Even
mice that had been rendered normoglycemic with anti-CD3
mAb had their tolerance broken by treatment with rapamycin.
Other studies have combined immunologic approaches with
approaches aimed at restoring b cell function to achieve glyce-
mic control. For example, the combination of a glucagon-like
peptide 1 (GLP-1) receptor agonist (Exendin-4) was found to
augment b cell function in diabetic mice treated with anti-CD3
mAb or ATG (Ogawa et al., 2004; Sherry et al., 2007). There
was little evidence for immune effects, but the insulin content
of pancreatic b cells was increased, possibly by enhancing
recovery of degranulated b cells that can be identified in islets
at the time of diagnosis.
There are few completed human trials with combinations of
immune modulators, in part because of the regulatory issues
involved with testing unapproved drugs. Published studies
have been limited to agents that have previously been approved
for use in other illnesses. A combination trial of IL-2 with rapamy-
cin, supported by the Immune Tolerance Network, is underway.
This approach is based on the complementary actions of the two
agents to cause activation-induced cell death with sparing and
perhaps expansion of Treg cells. An older study involved the
combination of azathioprine and prednisone, which showed effi-
cacy comparable to other agents such as CSA (Silverstein et al.,
1988). The most notable combination has been the use of
autologous nonmyeloablative hematopoietic stem cell trans-
plantation in subjects with new-onset T1D. Subjects received
pretreatment with cyclophosphamide and granulocyte-colony
stimulating factor (G-CSF) to expand CD34+ cells that were
harvested and reinfused after treatment of subjects with ATG
and cyclophosphamide. Unlike the experience in other immune
modulation trials, 14 of 15 patients were rendered insulin free
for an average of 16 months (Couri et al., 2009; Voltarelli et al.,
2007). Toxicity was a clear problem; oligospermia was seen in
10 of 22 subjects, and one case of pneumonia was reported.
Nonetheless, the extent and duration of insulin recovery was
unequaled by other approaches.
Concluding Remarks
Antigen-induced and/or antigen-specific Treg cell-mediated
tolerance-based strategies targeting only autoreactive T cells
in the absence of long-term application of broad-based immuno-
regulatory or suppressive drugs or antibodies are the targeted
immunotherapies for prevention or early reversal of T1D. Ideally,
the tolerance therapy would specifically target b cell antigens
involved in initiation of disease pathogenesis as well as identified
endogenous islet autoantigens, which may be recruited to
become targets of the ongoing autoimmune disease process
via epitope spreading. Antigen- or Treg cell-induced tolerance
therapies must also be durable, i.e., have the ability to regulate
the autoimmune response permanently or at least for many years
after induction, perhaps acting in part via the activity of renew-
able populations of autoantigen-specific Treg cells. Depending
on the status of the autoimmune repertoire at the time therapy
is initiated, tolerance induction may also have to be combined
with or induced shortly after a tolerable immunoregulatory treat-ment (small-molecule- or antibody-based), which can function to
reduce the autoantigen-specific T cell frequency to a level that
can be effectively and durably suppressed. In addition, addi-
tional drugs may be required in combination to promote b cell
regeneration. Regardless of the tolerance method employed
for therapy, early intervention in T1D patients is critical to prevent
ongoing islet destruction and to establish a microenvironment
conducive to allow for the recovery of a normal b cell mass
from endogenous progenitor cells. The chances for disease
prevention will be improved by the identification of biomarkers
identifying patients at risk as early in the disease process as
possible.
Cellular adoptive-transfer-based approaches have shown
significant promises in preclinical NOD models, both in predia-
betic and postdiabetic stages. Specifically, both ex vivo
expanded nTreg cells or induced CD4+CD25+Foxp3+ Treg cells
(iTreg cells) have been shown to control ongoing autoimmunity
and either prevent progression to overt diabetes or protect
syngeneic islet grafts and/or allow unperturbed b cell recovery,
thereby inducing diabetes remission in NOD mice (Godebu
et al., 2008; Luo et al., 2007; Tang et al., 2004; Weber et al.,
2006). It is unclear whether antigen specificity is critically impor-
tant in this approach because both nonspecifically expanded or
induced Treg cells and islet antigen-specific Treg cells have
shown efficacy in controlling the disease. Additionally, it also
appears that Treg cells of one antigen specificity may be suffi-
cient in controlling ongoing autoimmunity that is probably
caused by autoaggressive T cells of multiple islet antigen spec-
ificities (Luo et al., 2007; Tarbell et al., 2004). Clearly delineating
these characteristics of Treg cell adoptive-transfer therapy will
have significant impact on the design of future clinical trials using
this modality.
Another strategy for enhancing Treg cell numbers in vivo is by
dendritic cell-based therapy. It has been shown that direct injec-
tion of either dendritic cells from pancreatic draining lymph
nodes or b cell antigen-pulsed immature dendritic cells protects
prediabetic NOD mice from developing overt diabetes, possibly
through the in vivo induction of Treg cells (Clare-Salzler et al.,
1992; Lo et al., 2006). However, direct ex vivo dendritic cell
therapy carries the potential risk of their acquiring an activated
phenotype upon adoptive transfer, leading to ultimate immunity
rather than tolerance. An alternative approach for targeting
dendritic cells for tolerance induction is by the in vivo delivery
of cognate antigens to steady-state dendritic cells through the
endocytic receptor DEC 205 (Bonifaz et al., 2002). It has been
recently shown that delivery of b cell antigens in such a fashion
leads to deletion of diabetogenic CD8+ T cells in the context of
ongoing autoimmunity (Mukhopadhaya et al., 2008). Ultimately,
adoptive cell therapies that target both the CD4 and the CD8
compartments (Han et al., 2005; Santamaria, 2008) may provide
synergy for protection against ongoing autoimmunity.
The question then becomes what is the ideal therapy to
treat patients with long-standing T1D who have presumably
destroyed all or the majority of their b cell mass, perhaps
including renewable b cell progenitor cells? Again, tolerance-
based therapies would be ideal in early onset, but intervention
late in disease would still require that pancreatic autoantigen-
specific processes be targeted prior to the transplant of stem
cells capable of differentiation into insulin-producing b cells orImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 495
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Reviewby transplantation of allogeneic (islets harvested from cadaver
donors) or xenogeneic (e.g., porcine islet) islet cells. The critical
requirement for autoantigen tolerance in advanced disease is
amply illustrated by the fact that healthy islets from young
NODs transplanted into long-term diabetic NOD recipients are
vigorously rejected because of the residual autoimmune
responses (Tian et al., 1996) and by anecdotal human data
where pancreas transplants from identical twins are rejected
(Sibley et al., 1985). Assuming that the immunosuppressive
drugs required for the conditioning and/or maintenance of
allo- or xenografts may not be compatible with induction or
maintenance of autoantigen-specific tolerance, future therapies
attempting reversal of overt diabetes in long-standing T1D
patients secondary to islet transplantation will probably require
tolerance to diabetogenic autoantigens combinedwith tolerance
to the alloantigens or xenoantigens on the donor islets, an
approach currently under testing in the NOD model using
ECDI-fixed cells (Luo et al., 2008).ACKNOWLEDGMENTS
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